Bill > A5409

This bill requires NJ FamilyCare, which is New Jersey's Medicaid and Children's Health Insurance Program, to change how it reimburses inpatient providers for long-acting injectable antipsychotic drugs. Specifically, the bill mandates that reimbursement for these drugs administered in an inpatient setting must be separate from the standard Diagnostic Related Group (DRG) reimbursement system and must be at the same rate as the reimbursement for the same drugs when administered in an outpatient setting. The bill defines long-acting injectable antipsychotic drugs as FDA-approved medications that can treat psychiatric disorders like schizophrenia and bipolar disorder with a single dose lasting up to 24 weeks. Additionally, the bill introduces a provision allowing pharmacists to administer these injectable drugs, provided they are appropriately educated and qualified as determined by the New Jersey State Board of Pharmacy. The bill also directs the Commissioner of Human Services to apply for necessary state plan amendments, adopt implementing regulations, and prepare for the act's implementation, which will take effect four months after enactment.

Health and Social Services

https://www.njleg.state.nj.us/bill-search/2024/A5409